You are here

Provention Bio

Pfizer's fortunes overshadow first-quarter dealmaking

Pfizer's fortunes overshadow first-quarter dealmaking

EP Vantage

Flag link:

Sanofi's Provention buyout hit with FTC delay. Will Pfizer's Seagen deal go off as planned?

Sanofi's Provention buyout hit with FTC delay. Will Pfizer's Seagen deal go off as planned?

Fierce Pharma

Flag link:

Biopharma stocks go back to bleak

Biopharma stocks go back to bleak

EP Vantage

Apellis Pharmaceuticals

Protagonist Therapeutics

Reata Pharmaceuticals

Flag link:

Sanofi throws down $2.9B to acquire diabetes partner Provention Bio

Sanofi throws down $2.9B to acquire diabetes partner Provention Bio

Fierce Pharma

Flag link:

Delaying type 1 diabetes progression: major trial readouts to watch in 2023

Delaying type 1 diabetes progression: major trial readouts to watch in 2023

Clinical Trials Arena

clinical trials

type 1 diabetes

Flag link:

FDA greenlights Provention Bio's diabetes drug

FDA greenlights Provention Bio's diabetes drug

Yahoo/Reuters

type 1 diabetes

Flag link:

Anticipating FDA Yes, Provention Inks Co-Promotion Deal with Sanofi for T1D Drug

Anticipating FDA Yes, Provention Inks Co-Promotion Deal with Sanofi for T1D Drug

BioSpace

type 1 diabetes

Flag link:

Brace for an end-of-year boost to drug approvals

Brace for an end-of-year boost to drug approvals

EP Vantage

Alnylam Pharmaceuticals

Apellis Pharmaceuticals

Bristol Myers Squibb

Gilead Sciences

Mirati Therapeutics

Moderna Therapeutics

TG Therapeutics

Travere Therapeutics

Flag link:

Provention’s embattled diabetes med delayed again by FDA to consider new info

Provention’s embattled diabetes med delayed again by FDA to consider new info

Fierce Biotech

Flag link:

FDA sets August decision date for Provention’s type 1 diabetes drug

FDA sets August decision date for Provention’s type 1 diabetes drug

Pharmaforum

type 1 diabetes

Flag link:

Provention will wait for FDA to 'opine' on new data after teplizumab rejection, eyes Q4 for further talks

Provention will wait for FDA to 'opine' on new data after teplizumab rejection, eyes Q4 for further talks

Fierce Biotech

type 1 diabetes

Flag link:

Big pharma leads the way in stock market resurgence

Big pharma leads the way in stock market resurgence

EP Vantage

Acadia Pharmaceuticals

Moderna Therapeutics

Flag link:

Provention Bio slapped with FDA rejection for diabetes hopeful teplizumab

Provention Bio slapped with FDA rejection for diabetes hopeful teplizumab

Fierce Biotech

type 1 diabetes

complete response letter

Flag link:

FDA Action Alert: Vericel and Provention Bio

FDA Action Alert: Vericel and Provention Bio

BioSpace

type 1 diabetes

Flag link:

FDA adcomm votes in favor of approving Provention Bio’s drug to delay type 1 diabetes

FDA adcomm votes in favor of approving Provention Bio’s drug to delay type 1 diabetes

Endpoints

type 1 diabetes

Flag link:

Provention Bio, in need of AdComm's support for diabetes drug, may have what it needs to satisfy the FDA

Provention Bio, in need of AdComm's support for diabetes drug, may have what it needs to satisfy the FDA

Fierce Biotech

advisory panels

Flag link:

Provention warns FDA requests could delay diabetes approval

Provention warns FDA requests could delay diabetes approval

Fierce Biotech

type 1 diabetes

Flag link:

Provention Bio gives update on teplizumab BLA, FDA feedback

Provention Bio gives update on teplizumab BLA, FDA feedback

Seeking Alpha

type 1 diabetes

Flag link:

After midstage flop, Janssen says thanks but no thanks to Provention Bio drug

After midstage flop, Janssen says thanks but no thanks to Provention Bio drug

Fierce Biotech

Crohn’s disease

Flag link:

Pages